<![CDATA[Insights]]>https://insights.citeline.comTue, 12 Nov 2024 09:40:51 +0000en1hourly1<![CDATA[Japan H1 Roundup: Forex Impact, Strong Global Mainstays Positive Factors ]]>https://insights.citeline.com/scrip/japan-h1-roundup-forex-impact-strong-global-mainstays-positive-factors-PJXPS55ZSBFPZPUVU33BEHK4DE/https://insights.citeline.com/scrip/japan-h1-roundup-forex-impact-strong-global-mainstays-positive-factors-PJXPS55ZSBFPZPUVU33BEHK4DE/Mon, 11 Nov 2024 09:09:00 +0000<![CDATA[Eisai Cuts US Leqembi Sales Forecast But Japan, China Exceed Expectations]]>https://insights.citeline.com/scrip/business/earnings/eisai-cuts-us-leqembi-sales-forecast-but-japan-china-exceed-expectations-LVF5AVGQSBH4ZA6O2UVGCLPHMI/https://insights.citeline.com/scrip/business/earnings/eisai-cuts-us-leqembi-sales-forecast-but-japan-china-exceed-expectations-LVF5AVGQSBH4ZA6O2UVGCLPHMI/Mon, 11 Nov 2024 23:32:34 +0000<![CDATA[Value Of AbbVie’s Cerevel Buy Uncertain After Schizophrenia Failure]]>https://insights.citeline.com/scrip/r-and-d/clinical-trials/value-of-abbvies-cerevel-buy-uncertain-after-schizophrenia-failure-H4DMM5A3INHV3IXLCN64CAMR3E/https://insights.citeline.com/scrip/r-and-d/clinical-trials/value-of-abbvies-cerevel-buy-uncertain-after-schizophrenia-failure-H4DMM5A3INHV3IXLCN64CAMR3E/Mon, 11 Nov 2024 22:50:29 +0000<![CDATA[Pipeline Watch: Sanofi/Regeneron’s Dupixent Gets EU Eosinophilic Esophagitis Approved For Young Children]]>https://insights.citeline.com/scrip/r-and-d/pipeline-watch/pipeline-watch-sanofiregenerons-dupixent-gets-eu-eosinophilic-esophagitis-approved-for-young-children-VHKLSHWLKVGSXND26LSLTFDI2U/https://insights.citeline.com/scrip/r-and-d/pipeline-watch/pipeline-watch-sanofiregenerons-dupixent-gets-eu-eosinophilic-esophagitis-approved-for-young-children-VHKLSHWLKVGSXND26LSLTFDI2U/Mon, 11 Nov 2024 15:05:01 +0000<![CDATA[Almirall Insists Costly Ebglyss Launch Is Progressing Well]]>https://insights.citeline.com/scrip/business/earnings/almirall-insists-costly-ebglyss-launch-is-progressing-well-JGVUHZGENBDBVKZEMMYWGYTMNI/https://insights.citeline.com/scrip/business/earnings/almirall-insists-costly-ebglyss-launch-is-progressing-well-JGVUHZGENBDBVKZEMMYWGYTMNI/Mon, 11 Nov 2024 15:27:29 +0000<![CDATA[Muscling Into The Obesity Market]]>https://insights.citeline.com/scrip/business/strategy/muscling-into-the-obesity-market-HHUWSZFWXJA33BUB2VAGEATRYQ/https://insights.citeline.com/scrip/business/strategy/muscling-into-the-obesity-market-HHUWSZFWXJA33BUB2VAGEATRYQ/Mon, 11 Nov 2024 15:59:49 +0000<![CDATA[Autolus’s Newly Approved CAR-T Aucatzyl Could Take The Lead On Safety]]>https://insights.citeline.com/scrip/advanced-therapies/cell-therapies/autoluss-newly-approved-car-t-aucatzyl-could-take-the-lead-on-safety-ZI6R3Y6CGNCFJGDIOED2OFI5JQ/https://insights.citeline.com/scrip/advanced-therapies/cell-therapies/autoluss-newly-approved-car-t-aucatzyl-could-take-the-lead-on-safety-ZI6R3Y6CGNCFJGDIOED2OFI5JQ/Mon, 11 Nov 2024 16:56:33 +0000<![CDATA[Rapt Scraps Zelnecirnon, But Not Giving Up On CCR4]]>https://insights.citeline.com/scrip/therapeutic-category/immunological/rapt-scraps-zelnecirnon-but-not-giving-up-on-ccr4-RZ22FTLM4RGTVBY6BVWTWIMX5U/https://insights.citeline.com/scrip/therapeutic-category/immunological/rapt-scraps-zelnecirnon-but-not-giving-up-on-ccr4-RZ22FTLM4RGTVBY6BVWTWIMX5U/Mon, 11 Nov 2024 20:38:37 +0000<![CDATA[Profile: MSD, Janssen To BSV-Mankind Deal, Navangul’s Journey Is A Rich Mosaic]]>https://insights.citeline.com/scrip/profile-msd-janssen-to-bsv-mankind-deal-navanguls-journey-is-a-rich-mosaic-OZCIEED74ZAXHKYY4JFLBUWWSY/https://insights.citeline.com/scrip/profile-msd-janssen-to-bsv-mankind-deal-navanguls-journey-is-a-rich-mosaic-OZCIEED74ZAXHKYY4JFLBUWWSY/Mon, 11 Nov 2024 07:41:40 +0000<![CDATA[Quick Listen: Scrip's Five Must-Know Things]]>https://insights.citeline.com/scrip/quick-listen-scrips-five-must-know-things-D4FI3E5BCNF2HNIP6TPK5KQ2A4/https://insights.citeline.com/scrip/quick-listen-scrips-five-must-know-things-D4FI3E5BCNF2HNIP6TPK5KQ2A4/Mon, 11 Nov 2024 02:40:27 +0000